KAS
AQST icon

Kestra Advisory Services’s Aquestive Therapeutics AQST Stock Holding History

Kestra Advisory Services’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-86,350
Closed -$98.4K – 2106
2023
Q1 		$98.4K Buy
+86,350
New +$74.8K ﹤0.01% 1955

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kestra Advisory Services's AQST Position: Q2 2023 in Review

Kestra Advisory Services sold out of Aquestive Therapeutics (AQST) in Q2 2023, closing a stake of 86,350 shares — an estimated $98.4K sold.

Kestra Advisory Services first reported a position in AQST in Q1 2023 and held it in 1 quarter. The position peaked at $98.4K in Q1 2023. 54 funds tracked by Wall St. Rank hold AQST as of Q2 2023.

  • Kestra Advisory Services reported no remaining Aquestive Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Kestra Advisory Services sold 86,350 Aquestive Therapeutics shares in Q2 2023, an estimated $98.4K.
  • Kestra Advisory Services first reported a position in Aquestive Therapeutics in Q1 2023 and held it in 1 quarter.
  • Kestra Advisory Services's Aquestive Therapeutics position peaked at $98.4K in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2023.

Based on Kestra Advisory Services's 13F filing for Q2 2023, filed 11 Aug 2023.